CoronaryAtlas logo
CoronaryAtlas
Troponin T
Pathway / Myocardial injury (shared endpoint)

Troponin T

TNNT2protein

Cardiac troponin T is released from damaged cardiomyocytes following myocardial ischemia and necrosis and is the primary biomarker for acute MI diagnosis, prognosis, and risk stratification.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencehigh
RationaleCardiac contractile protein released upon myocardial necrosis; gold-standard biomarker for AMI diagnosis and risk stratification.
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableYes
Antibody tractableNo
EnsemblENSG00000118194

Type I vs Type II discrimination

ScoresShared / rises in both
R — rupture / Type-I
100
C — confounder / Type-II
60
A — assay feasibility
96
E — evidence strength
85
T1DI (composite)
57
Specificity differential (R−C)+40
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
3hypovolemia / dehydrationn/a
4tachyarrhythmiamag 1
5hypoxemia / respiratory failuremag 2
6hypertensive emergencymag 2
7high-demand / peri-operative stressmag 2
Coverage: 5/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 27 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma (Li-heparin)
Collection tube
Lithium heparin (green-top) · Serum separator (gold/red-top, SST)
Method / principle
High-sensitivity ECL sandwich immunoassay
Reagent / substrate
Anti-cTnT monoclonal antibody pair, ruthenium label
Platform
Roche cobas/Elecsys (sole cTnT supplier)
Turnaround · availability
STAT (~18 min) · FDA-cleared

Human genetic evidence

0.266
Open Targets association (acute_MI)

Literature evidence(47)

Showing 40 of 47 linked references.

Clinical trials(6)